Novartis, CH0012005267

Novartis enters deal with USD 900 million milestones. Novartis stock trades below EUR 125.65

Published on 10/01/2026 at 12:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis can receive up to USD 900 million in milestones. Novartis stock costs EUR 125.35 on October 1, 2026, minus 0.24 percent versus EUR 125.65.

Forscherin in weißem Kittel pipettiert in Reagenzglas im sterilen Pharmalabor — Novartis AG CH0012005267 – Forscherin pipettiert präzise in steriler Pharmalaborumgebung mit Reagenzgläsern, Illustration mit AI erstellt.

Novartis (ISIN CH0012005267) entered an exclusive global license agreement for a preclinical radioligand therapy asset, with milestone payments that can reach USD 900 million. MarketScreener reported the agreement on September 22, 2026, identifying BoomRay as the licensor and Novartis as the global development partner.

License deal adds pipeline optionality

The agreement covers an undisclosed preclinical asset in radioligand therapy, an area in which Novartis already has specialized development and commercial capabilities. BoomRay can receive up to USD 900 million, including an upfront payment and development, regulatory and sales milestones, while future sales may generate royalties.

The deal is small relative to the wider company, but its structure limits the immediate financial commitment while preserving access to a potential new medicine. That matters after several late-stage setbacks have shifted attention from acquisition volume to development execution.

Trial setbacks raise acquisition scrutiny

Reuters reported on September 8, 2026, that del-desiran failed a late-stage study and that Novartis had missed two of three key pipeline tests during the year. The report also said Novartis reiterated guidance for sales growth at a compounded annual rate of 5.00 percent to 6.00 percent between 2025 and 2030.

Reuters reported on September 10, 2026, that Artisan Partners called for stronger board oversight of acquisitions after the trial setbacks. Novartis said its financial guidance was unchanged and described its medicine pipeline as broad, leaving execution and capital allocation as the central issues for shareholders.

Results date keeps the calendar moving

The Novartis investor-relations page lists second-quarter 2026 results dated July 21, 2026, and the next reporting calendar points to third-quarter results on October 26, 2026. Novartis also lists a September 29, 2026 investor event, keeping pipeline communication central ahead of the next earnings release.

Novartis had a market capitalization of USD 271.0 billion as of September 30, 2026. The combination of a USD 900 million milestone opportunity and unchanged 5.00 percent to 6.00 percent long-term sales guidance gives the stock two different reference points: near-term pipeline confidence and longer-term portfolio replacement.

Novartis stock stays below prior close

Novartis stock was trading at EUR 125.35 at Lang & Schwarz on October 1, 2026 at 12:34 p.m. CEST, down 0.24 percent versus the Lang & Schwarz prior close of EUR 125.65 on September 30, 2026. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.